Correspondence 0001104659-24-054056 from SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc.
Date: April 29, 2024 · CIK: 0001390478 · Accession: 0001104659-24-054056

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-278334

Date

April 29, 2024

Author

Angelos M. Stergiou, M.D., Sc.D., h.c.

Form

CORRESP

Company

SELLAS Life Sciences Group, Inc.

Letter

Via EDGAR United States Securities and Exchange Commission Division of Corporate Finance Registration Statement on Form S-3 Filed March 28, 2024 File No. 333-278334 Acceleration Request

Dear Mr. Edwards,

Pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Registrant”) hereby respectfully requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278334), so that it may become effective at 5:00 p.m. (Washington, D.C. time) on Wednesday, May 1, 2024, or as soon thereafter as practicable.

Please call Daniel A. Bagliebter, of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any comments or questions regarding the Registration Statement.

Very truly yours,
SELLAS Life Sciences Group, Inc.

Show Raw Text

CORRESP
1
filename1.htm

SELLAS Life Sciences Group, Inc.

7 Times Square, Suite 2503

New York, New York 10036

 April 29, 2024

Via
EDGAR

Chris Edwards

United States Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: SELLAS Life Sciences Group, Inc.

  Registration Statement on Form S-3

  Filed March 28, 2024

  File No.  333-278334

  Acceleration Request

Dear Mr. Edwards,

Pursuant to Rule 461
of Regulation C promulgated under the Securities Act of 1933, as amended, SELLAS Life Sciences Group, Inc. (the “Registrant”)
hereby respectfully requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-278334),
so that it may become effective at 5:00 p.m. (Washington, D.C. time) on Wednesday, May 1, 2024, or as soon thereafter as practicable.

Please call Daniel A. Bagliebter,
of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any comments or questions regarding
the Registration Statement.

 Very truly yours,

  SELLAS Life Sciences Group, Inc.

  /s/ Angelos M. Stergiou

  By:
                                        Angelos M. Stergiou, M.D., Sc.D., h.c.

  Its:
                                         President and Chief Executive Officer

cc: Stacy E. Yeung, Esq., SELLAS Life Sciences Group, Inc.

  Daniel A. Bagliebter, Esq., Mintz, Levin,
Cohn, Ferris, Glovsky and Popeo, P.C.

SecProbe.io